HSBC Holdings
KPTI icon

HSBC Holdings’s Karyopharm Therapeutics KPTI Stock Holding History

HSBC Holdings’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.6K Buy
+11,495
New +$87.6K ﹤0.01% 2787
2025
Q1 		– Sell
-2,687
Closed -$26.5K – 3166
2024
Q4 		$26.5K Hold
2,687
– – ﹤0.01% 3042
2024
Q3 		$31K Sell
2,687
-852
-24% -$10.6K ﹤0.01% 2918
2024
Q2 		$48.1K Sell
3,539
-32
-0.9% -$530 ﹤0.01% 2822
2024
Q1 		$80.9K Buy
3,571
+552
+18% +$9.68K ﹤0.01% 2878
2023
Q4 		$38.9K Buy
3,019
+24
+0.8% +$323 ﹤0.01% 2661
2023
Q3 		$60.4K Buy
2,995
+2,176
+266% +$48.8K ﹤0.01% 2610
2023
Q2 		$22.3K Hold
819
– – ﹤0.01% 2519
2023
Q1 		$46.8K Buy
+819
New +$40.4K ﹤0.01% 2570
2021
Q2 		– Sell
-949
Closed -$149K – 3007
2021
Q1 		$149K Sell
949
-486
-34% -$102K ﹤0.01% 2591
2020
Q4 		$330K Buy
1,435
+155
+12% +$35.9K ﹤0.01% 2503
2020
Q3 		$283K Buy
1,280
+34
+3% +$8.32K ﹤0.01% 2287
2020
Q2 		$354K Buy
1,246
+353
+40% +$104K ﹤0.01% 2038
2020
Q1 		$252K Buy
+893
New +$246K ﹤0.01% 2158

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

HSBC Holdings's KPTI Position: Q1 2026 in Review

HSBC Holdings opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 11,495 shares worth $65.6K. The stake represents ﹤0.01% of the portfolio and ranks #2787 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in KPTI as recently as Q4 2024.

HSBC Holdings first reported a position in KPTI in Q1 2020 and has held it in 14 quarters since. The position peaked at $354K in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • HSBC Holdings held 11,495 shares of Karyopharm Therapeutics worth $65.6K as of Q1 2026.
  • Karyopharm Therapeutics was a new HSBC Holdings position in Q1 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2787 holding.
  • HSBC Holdings first reported a position in Karyopharm Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • HSBC Holdings's Karyopharm Therapeutics position peaked at $354K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.